Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2363-2374

  Picarda, Gaëlle ^a   Lamoureux, François ^a   Geffroy, Loïc ^b   Delepine, Pascal ^c   Montier, Tristan ^c   Laud, Karine ^d   Tirode, Franck ^d   Delattre, Olivier ^d   Heymann, Dominique ^a   Rédini, Françoise ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CELL VIABILITY; CHILD; CONTROLLED STUDY; EWING SARCOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL;

EID: 77950980364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1779     Document Type: Article

References (49)

1. Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F, Rédini F. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther 2007;7: 169-181 (Pubitemid 46277282)
2. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6.
3. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc 1921;21: 17-22
4. Hense HW, Ahrens S, Paulussen M, et al. Descriptive epidemiology of Ewing's tumors: analysis of German patients from (EI)CESS 1980-1997. Klin Padiatr 1999;211:271-275
5. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents 1978-1997. Report from the Automated Childhood Cancer Information System Project. Eur J Cancer 2006;42:2124-2135
6. Lau YS, Adamopoulos IE, Sabokbar A, Giele H, Gibbons CLMH, Athanasou NA. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. Br J Cancer 2007;96:1716-1722 (Pubitemid 46847198)
7. Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. Am J Surg Pathol 1984;8:885-898
8. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 2001;25:1061-1066
9. May WA, Gishizky ML, Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993;90:5752-5756
10. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/ CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein. J Biol Chem 2003;278:15105-15115 (Pubitemid 36799844)
11. Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001;20:3258-3265 (Pubitemid 32553678)
12. Cohen MD, Bugaieski EM, Haliloglu M, Faught P, Siddiqui AR. Visual presentation of the staging of pediatric solid tumors. Radiographics 1996;16:523-545 (Pubitemid 126448682)
13. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study. J Clin Oncol 2000; 18:3108-3114
14. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005;10:35-51. (Pubitemid 40575634)
15. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006;110:279-291
16. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-237 (Pubitemid 40315182)
17. Liabakk NB, Espevik T. Monoclonal antibodies against TRAIL. Vitam Horm 2004;12:65-79.
18. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008;263:14-25.
19. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-1395 (Pubitemid 46706887)
20. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-6194 (Pubitemid 350075080)
21. Marini P. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr Opin Mol Ther 2006;8: 539-546 (Pubitemid 44921810)
22. Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J. Resistance of melanoma cells to TRAIL does not result from upregulation of anti-apoptotic proteins by NF-êB but is related to downregulation of initiator caspases and DR4. Oncogene 2007;26:3364-3377 (Pubitemid 46788891)
23. Martínez-Ramírez A, Rodríguez-Perales S, Meléndez B, et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2003;141:138-142 (Pubitemid 36269213)
24. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 2002;188:213-219 (Pubitemid 35292347)
25. Klein B, Pals S, Masse R, et al. Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer 1977;20:112-119 (Pubitemid 8139751)
26. Joliat MJ, Umeda S, Lyons BL, Lynes MA, Shultz LD. Establishment and characterization of a new osteogenic cell line (MOS-J) from a spontaneous C57BL/6J mouse osteosarcoma. In Vivo 2002;16: 223-228
27. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
28. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006;28:261-269
29. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Rédini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005;104:2522-2529 (Pubitemid 41691577)
30. Floch V, Loisel S, Guenin E. Cation substitution in cationic phosphonolipids: a new concept to improve transfection activity and decrease cellular toxicity. J Med Chem 2000;43:4617-4628
31. Floch V, Delépine P, Guillaume C, et al. Systemic administration of cationic phosphonolipids/DNA complexes and the relationship between formulation and lung transfection efficiency. Biochim Biophys Acta 2000;1464:95-103. (Pubitemid 30110520)
32. Scotlandi K, Benini S, Manara MC, et al. Murine model for skeletal metastases of Ewing's sarcoma. J Orthop Res 2000;18:959-966 (Pubitemid 32055767)
33. Evdokiou A, Bouralexis S, Atkins GJ, et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99: 491-504. (Pubitemid 34461601)
34. Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ 2001;8:506-514 (Pubitemid 32492771)
35. Merchant M S, Yang X, Melchionda F, et al. Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004;64:8349-8356 (Pubitemid 39491774)
36. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-8633 (Pubitemid 38019198)
37. Kelley RF, Totpal K, Lindstrom SH, et al. receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis fctor-apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;208:2205-2212
38. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004;5:501-512 (Pubitemid 38610251)
39. Mahalingam D, Szegezdi E, Keane M, Jong SD, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009;35:280-288
40. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162
41. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004;64:4900-4905 (Pubitemid 38924535)
42. Shankar S, Ramsing Singh T, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004;24:1133-1140
43. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007;67:7308-7318 (Pubitemid 47206560)
44. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889;1:571-572
45. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10:159-178
46. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004;4:308-318
47. Grosse-Wilde A, Voloshanenko O, Bailey SL, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-110
48. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family of tumors are sensitive to tumor necrosis factor-related apoptosis inducing ligand and express death receptor 4 and 5. Cancer Res 2001;61:2704-2712 (Pubitemid 32685858)
49. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-385 (Pubitemid 32298514)